Mass Spectrometry and the Amyloid Problem—How Far Can We Go in the Gas Phase?  by Ashcroft, Alison E.
CRITICAL INSIGHT
Mass Spectrometry and the Amyloid
Problem—How Far Can We Go in the
Gas Phase?
Alison E. Ashcroft
Astbury Centre for Structural Molecular Biology, Institute of Molecular and Cellular Biology, University of
Leeds, Leeds, United Kingdom
A number of proteins are capable of converting from their soluble, monomeric form into highly-
ordered, insoluble aggregates known as amyloid fibrils. In vivo, these fibrils, which accumulate in
organs and tissues, are associated with a wide range of amyloid diseases for which there are currently
no therapeutic solutions. The molecular details of the pathway from native monomer through
oligomeric intermediates to the final amyloid fibril remain a challenging enigma. Over the past few
years,mass spectrometry has been applied to investigate the various stages of amyloid fibril formation,
and this report summarizes the key steps achieved to date. (J Am Soc Mass Spectrom 2010, 21,
1087–1096) © 2010 American Society for Mass SpectrometryAmyloidosis has been puzzling scientists forsome 150 years when the name amyloid, derivedfrom amylum (Latin) and amylon (Greek), both
meaning starch, was first proposed by Rudolph Vir-
chow on account of the cellulose-like qualities of a brain
tissue abnormality he had observed [1, 2]. In fact,
amyloid deposits are composed of protein fibrils and in
principle there is one type of protein in each case of
amyloidosis [3]. There are 20 such (quite different)
proteins that undergo amyloidosis in humans in vivo
and which are associated with a variety of diseases,
including Alzheimer’s, Parkinson’s, Huntington’s,
hemodialysis-related amyloidosis, and the spongiform
encephalopathies (Table 1) [4]. Although these proteins
have no apparent similarities in terms of amino acid
sequence or tertiary structure, the fibrils they produce
show a high degree of resemblance in their external
morphology [5] and characteristics, which include low
solubility and an unbranched structure with an ex-
tended cross- sheet central core that can be detected
using X-ray diffraction [6], observation of birefringence
with the dye Congo red [7], and chemical binding to
Thioflavin T [8]. Moreover, it has been reported that
amyloid formation is possible in vitro under chosen
conditions for all peptide chains regardless of their
sequence [9].
Although it is generally acknowledged that amyloid-
osis is a clinically and biochemically heterogeneous
group of protein folding/misfolding disorders accom-
panied by self-aggregation, we have still much to learn
about the amyloid fibril assembly pathways, precisely
Address reprint requests to Dr. A. E. Ashcroft, Astbury Centre for Struc-
tural Molecular Biology, Institute of Molecular and Cellular Biology, The
University of Leeds, Leeds LS2 9JT, UK. E-mail: a.e.ashcroft@leeds.ac.uk
© 2010 American Society for Mass Spectrometry. Published by Elsevie
1044-0305/10/$32.00
doi:10.1016/j.jasms.2010.02.026which species are the culprits of disease, and how to
prevent the debilitating diseases caused by this phe-
nomenon. So what are the difficulties involved in
understanding these polymerization reactions? The
complexity of the situation is illustrated in Figure 1 [10].
First, the protein monomer may well be present in a
co-populated mixture of folded, partially folded, and
highly unfolded families of conformers, any one (or
more) of which may be capable of initiating the assem-
bly process [11]. Next, although early reports indicated
that the amyloid fibrils were the primary pathogenic
agent, recent evidence has suggested that smaller ag-
gregates populated during fibril assembly are more
likely to be responsible for pathogenesis [12–15]; for
example, it has been suggested that A oligomers could
be the cause, rather than a product of, Alzheimer’s
disease [16]. This suggestion makes the characterization
of all species present within the heterogeneous ensem-
bles that exist during the aggregation process both
necessary and highly important. Additional points of
concern to the analyst are that fibril formation is sto-
chastic, many of the noncovalently bound, macromolec-
ular intermediate species are transient and present in
barely discernible quantities, and also there is the
possibility that some aggregation species may be dead-
end, rather than on-pathway, products. In fact, out of all
the species to be considered within this complex reac-
tion scheme, the amyloid fibril itself, despite its size and
insolubility, is the easiest to identify [albeit not by mass
spectrometry (MS)] due to its longevity and consistently-
ordered structure.
Low-resolution details of intact amyloid fibrils,
which can be generated by electron microscopy (EM)
[17], cryo-EM [18], and atomic force microscopy (AFM)
[19, 20], have shown that fully assembled amyloid
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either intertwined into helices or bound side-to-side
in a twisted ribbon structure [21, 22], in which the
-strands are arranged perpendicular to the fibril axis.
Table 1. The more common amyloid diseases and their
associated proteins
Disease Protein
Alzheimer’s A, from amyloid
precursor protein (APP)
Atherosclerosis Apolipoprotein A1
Dialysis-related amyloidosis 2-Microglobulin (2m)
Familial amyloid
polyneuropathy
Transthyretin
Familial non-neuropathic
amyloidosis
Lysozyme
Huntington’s Huntingtin
Injection-localized amyloidosis Insulin
Medullary thyroid carcinoma Calcitonin
Parkinson’s a-Synuclein
Pituitary gland amyloidosis Prolactin
Primary systemic amyloidosis Immunoglobulin (Ig) light
chain
Rheumatoid arthritis Serum amyloid A
Transmissible spongiform
encephalopathies
Prion
Type II diabetes Islet amyloid polypeptide
(IAPP)
Figure 1. Taken from [10] (Figure 1). A sch
aggregation. The surface shows the multitude o
via intramolecular contact formation, or toward
contacts. Reprinted by permission from FEBS LettersTo date, the fully assembled fibrils have not been
detected in their intact forms by MS, due to their size,
intractability, and heterogeneity.
However, MS, and in particular electrospray ioniza-
tion (ESI)-MS, comes into its own in the analysis of
heterogeneous populations of soluble species of differ-
ing mass or mass-to-charge ratio (m/z) and, when cou-
pled to ion mobility spectrometry (IMS), of differing
collision cross-section also. Not only does MS provide
the opportunity for such species to be identified—even
as minor entities—within mixtures, it offers the means
to monitor the appearance and disappearance of indi-
vidual species during a reaction pathway, thus afford-
ing a distinct advantage over complementary biophys-
ical techniques, including circular dichroism (CD),
nuclear magnetic resonance (NMR), and Fourier trans-
form infrared (FT-IR), which yield population-average
data. Furthermore, the small amounts of sample re-
quired, the ability to maintain noncovalent interactions
in the gas phase, and the speed of data acquisition
render ESI-MS ideal for monitoring protein aggregation
in real-time, directly from the reaction solution.
Despite this apparent panacea, there remain funda-
mental issues to consider: can MS, a gas-phase technique,
reveal useful insights into solution phase amyloid fibril
formation? How can we copy in vivo amyloid fibril
formation in vitro, in particular under MS-compatible
tic energy landscape for protein folding and
formations ‘funneling’ towards the native state
formation of amyloid fibrils via intermolecularema
f con
s the: FEBS Lett. 2005, 272, 5962–5970.
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reproduce the complex environment of the cell perfectly
in the laboratory, we must bear in mind that what we
detect may not be relevant to in vivo amyloidosis and
strive to obtain supporting information from a range of
complementary biophysical and chemical techniques.
The aim of this article is to assess how far we have
advanced with our quest to decipher the intriguing
questions posed by the amyloid problem using MS, in
terms of protein folding and misfolding, oligomer for-
mation during the assembly pathway, intact amyloid
structure, and finally, ways in which we can influence
assembly externally.
Step-by-Step Amyloid Assembly with
Mass Spectrometry
What Can We Learn About Protein Conformers?
Early ESI-MS experiments illustrated that the m/z charge
state distribution of a protein depended on its folded
state, with a more folded protein having a narrower
charge state distribution with fewer charges on average
than the same protein analyzed under alternative solu-
tion conditions which favor a less folded conformation
[23]. To date, the relationship between ESI-MS charge
state distributions (i.e., protein conformation in the gas
phase) has correlated well with the conformational
properties of proteins in solution, thus supporting the
notion that protein structure in the solution phase can
be retained after ionization and, for some time, into the
gas phase [23, 24].
But what about a more realistic situation in which a
protein could populate a number of conformational
Figure 2. Taken from [29, 36] (Figure 7). ESI-T
versus intensity) showing the detection of three
dogenic protein 2-microglobulin at pH 2.6. The
(c) conformers have collision cross-sectional area
The inset on the right hand side shows the summedstates simultaneously? With ESI-MS analysis, a number
of overlapping charge state distributions may ensue,
making it difficult to assign the number of conforma-
tional states present and the relative abundance of each
one within an ensemble. As protein unfolding and
subsequent misfolding are thought to be key initial
steps in the amyloid-forming process, the identification
of different conformeric entities within a co-populated
ensemble of monomeric protein is of interest to amyloid
researchers. This feat can be achieved by IMS, which
has the ability to separate ions on account of their shape
and charge and has been shown to be particularly
successful when coupled to MS for separating a number
of co-populated conformers of varying shape arising
from a single protein [25–28]. This methodology has
proved effective recently for separating and identifying
co-populated conformers of the amyloidogenic protein
2-microglobulin (2m) [29]. 2m, a 99-residue protein
with a -sheet structure associated with the disorder
hemodialysis-related amyloidosis, is the light chain of
the major histocompatibility complex class 1 (MHC-1).
In vivo, monomeric 2m is shed continuously from the
surface of cells displaying MHC-1 molecules and in
healthy humans 95% of the free protein is removed
through the kidney. Renal failure results in an increase
in 2m concentration of 25-fold, leading to the depo-
sition of amyloid plaques in the joints [30, 31]. 2m
titration with concomitant detection and separation of
the co-populated conformers at each pH was achieved
[29] using the recently developed traveling wave IMS
(TWIMS)-MS system [32, 33] (Figure 2). Simultaneous
collision cross-section measurements of the protein con-
formers, achieved directly in conventional IMS-MS
S-MS data (drift time (mobility, ms) versus m/z
opulated families of conformers of the amyloi-
ed (a), partially unfolded (b) and acid-unfolded
) of 1317 Å2, 1775 Å2, and 2098 Å2, respectively.WIM
co-p
fold
s (sm/z spectrum over the entire experiment.
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[36–38] by calibration with a series of IMS-MS analyzed
standards [39], were also made. This method has
proven to be a useful and rapid method for assessing
the possible correlation between protein stability and
propensity for fibril formation, by comparing the wild-
type protein with a series of amino acid variants [29,
36].
Consequently, ESI-IMS-MS has armed us with
unique methodology that will measure the molecular
mass of a protein, separate co-populated families of
conformers within an ensemble, and provide informa-
tion regarding the relative physical sizes of each of
these conformeric groups in a single, rapid experiment,
thus paving the way forwards for individual protein
conformers to be monitored during fibril assembly, and
their interactions with potential therapeutic inhibitors
to be assessed.
Are Oligomers Amyloid Intermediates or
Dead-End Products and Can We Monitor Amyloid
Pathways In Vitro?
When analyzing noncovalently bound protein com-
plexes, their tertiary and quaternary structure can be
retained, at least to some extent, in the gas-phase during
the ESI-MS analysis. Applications covering a wide
range of complexes, often of very high molecular mass,
now appear with regularity in the literature, including
inter alia virus capsids [40], small heat shock proteins
[41], myosin VI complexes [42], and hemocyanins [43].
Thus, the study of oligomers arising from amyloido-
genic proteins, which is of high importance not only in
determining the amyloid pathway but also because
recent reports have indicated that oligomers may play a
key role in amyloid-related disease, is achievable.
Furthermore, the recent upsurge in interest in
IMS-MS has made a distinct impact on the characteriza-
tion of the 3D structures of noncovalently bound com-
plexes. In the case of amyloid-related oligomers, informa-
tion on the shape of each oligomeric species has been
achieved, either directly by conventional IMS-MS [44] or
indirectly by TWIMS-MS [45]. By comparing the mea-
sured cross-sectional areas with values calculated from 3D
coordinates using modeling programs, potential struc-
tural arrangements of subunits can be considered for these
complex biomolecules. The freely-available, web-based
Mobcal suite of modeling programs is frequently used for
this purpose. Mobcal consists of three different programs:
the projection approximation method originally from the
Bowers’ group [46] and the trajectory method and exact
hard sphere scattering calculations from Jarrold [47, 48].
More recent variations on the projection approximation
method have emerged [36, 49, 50].
Of course, there is always the ubiquitous question of
whether the oligomers present, both in solution and in
the gas phase, are true on-pathway amyloid intermedi-
ates or whether they are off-pathway aggregation spe-cies. This is an important issue that has been reviewed
by others, including discussions of a range of structural,
kinetic, and thermodynamic experimental evidence
[22, 51–53] and of the diversity of kinetic pathways in
amyloid formation [54].
Additionally, a number of concerns arise specifically
when considering the detection of protein aggregates
by ESI-MS. Is it possible to identify a multitude of
oligomers arising from a single protein unambiguously,
when they are likely to give rise to ions of the same m/z
ratios? Are the gas-phase oligomers we detect represen-
tative of the oligomers present in solution or could they
be artefacts of the ionization technique? Are some
species being suppressed during the analysis of these
heterogeneous mixtures? How do we know that fibril
formation in vivo can be reproduced in vitro, often in
buffers and solvents chosen for their MS-compatibility
rather than any physiologic reasons? The greater the
number of manuscripts that appear describing nonco-
valent protein complex analysis by MS, the more the
general scientific public accepts that MS gas-phase
studies can generate meaningful information on bio-
macromolecular systems. However, in practice it is
sensible to corroborate results with data from comple-
mentary biophysical techniques, whenever possible, to
avoid overenthusiastic conclusions being made. The
following case studies cover examples where these
issues have been successfully addressed.
An early paper reporting the ESI-MS detection of
oligomers in protein self-assembly systems focused on
insulin, a 51-amino acid residue protein, which forms
well-defined oligomers in its native state yet can be
induced to aggregate into amyloid fibrils under non-
physiologic conditions [55]. In vivo, insulin is stored in
the pancreas as a Zn2-containing hexamer composed
of three equivalent dimers, and it is this form that is
used in the treatment of type 1 diabetes. Following
administration, to achieve more efficient absorption
into the blood stream, the hexamers are broken down
into monomers and dimers, which are prone to fibrillar
self-assembly, thus limiting the therapeutic value of this
approach. ESI-MS analysis of insulin in the presence of
Zn2 led to the detection of monomers, dimers, tetram-
ers, and hexamers (the latter with two to four Zn2 ions
bound) [55]. The absence of odd-numbered oligomers
indicated that such species were not stable entities in
solution under these conditions and provided good
evidence that the oligomers detected had not been
generated artefactually during the ESI-MS process. At
lower pH, conditions under which insulin is known
to aggregate in solution, populations of higher order
oligomers up to and including the dodecamer were
detected. Increasing the temperature of the solution
caused the population of these oligomers to decline
rapidly, suggesting that their demise was connected
with the formation of higher order aggregates and
fibrils, the latter confirmed by EM.
A contemporary report was published on islet amy-
loid polypeptide (IAPP), a 37-residue C-terminally ami-
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sulin in the pancreas and, in its fibrillar form, is the
main component of diabetes-related amyloid plaques
[56]. ESI-MS was used to follow human IAPP amyloid
formation by monitoring monomer consumption,
whilst IAPP from rat (of similar ESI-MS sensitivity to
human IAPP) was employed as a non-fibrillogenic
control. Using this methodology, precursor consump-
tion in seeded reactions was found to follow first-order
kinetics, although the study did not identify any oligo-
meric species [56].
ESI-MS studies on the presence of 2-microglobulin
oligomers in amyloid fibril assembly in vitro were
complemented by analytical ultracentrifugation (AUC)
data to confirm the presence of oligomers in solution,
and formation of the final fibrils was verified by a
Thioflavin-T fluorescence test [57]. The ESI-MS data
indicated that whereas the worm-like fibrils, which
form with nucleation-independent kinetics at pH 3.6,
assemble by a mechanism consistent with sequential
monomer addition with species ranging from monomer
to 13-mer (inclusive) being detected en masse as tran-
sient assembly intermediates, in contrast only mono-
mers, dimers, trimers, and tetramers were observed
during nucleated fibril growth at pH 2.5, leading to the
formation of long, straight fibrils very similar in appear-
ance to those found ex vivo. These heterogeneous en-
sembles led to complicated spectra from which it was
difficult to assess the role in the assembly pathway of
any particular oligomer [57]. More recent ESI-IMS-MS
studies have succeeded in separating the oligomers
during the analysis, thus making possible the interro-
gation of individual oligomers [45].
Much research is directed at the widespread Alzhei-
mer’s disease in which the associated fibrils comprise
proteolytic fragments (A) of some 39 to 43 residues
derived from the 753-residue -amyloid precursor pro-
tein (APP) [58]. An early publication in this area fo-
cused on a model peptide corresponding to A10-30,
which contains the core region involved in A fibrillar
aggregation. Detection of A10-30 oligomers by ESI-MS
in 10 mM ammonium acetate solution led to the iden-
tification of monomer, dimer, trimer, tetramer, pen-
tamer, and hexamer [59]. From the highest amplitude
charge states observed for each oligomer, it was found
that the charge per monomeric subunit within these
oligomers decreased from monomer (3) to pentamer
(1.5), but then increased again for hexamer (1.8).
Thus, frommonomer to pentamer a gradual build-up of
structural compactness was observed, whilst for the
hexamer, the charge per monomeric subunit value
reverted almost to that of the dimer (2), indicating a
gross change in structural organization. Interestingly,
regardless of the peptide’s concentration, the sum of the
oligomeric peaks never exceeded 10% of the total re-
sponse. To gain further insight into the structural prop-
erties of these oligomers, isotope exchange studies, in
conjunction with ESI-MS, were performed. Hydrogen
deuterium exchange (HDX) indicated no difference inthe rate of exchange for monomers, dimers, and trimers
at neutral pH, suggesting either that there is a lack of
defined, stable structure in these oligomers or that there
is a fast exchange between oligomer subunits and the
pool of monomers. To measure the exchange rate be-
tween oligomers and the pool of monomers directly,
15N-labeled A10-30 was mixed with unlabeled peptide
and analyzed. Dimers and trimers both gave the ex-
pected ratio of unlabeled, mixed-labeled, and labeled
subunits (1:2:1 and 1:3:3:1, respectively), implying that
full subunit exchange had been achieved in a subsecond
time scale, and thus confirming that the lack of hydro-
gen shielding observed in the HDX experiment results
from fast monomer subunit exchange and does not
implicate a lack of definite structure in these oligomers.
A recent publication reported the elegant separation
and characterization of a number of co-populated A
oligomers using conventional IMS-MS [44, 60–62]. This
study indicated differences in the oligomers formed
from A1-42 compared with those formed from A1-
40, two species that adopt similar random coil struc-
tures in solution, although A1-42 forms amyloid fibrils
significantly faster than A1-40 [44, 60]. In vitro, A1-42
showed evidence for dimer, tetramer, hexamer, and
dodecamer oligomers, whilst only the dimer and tet-
ramer were detected in the case of A1-40, thus offering
plausible insights into why their contribution to amy-
loidosis is quite different (Figure 3). Collision cross-
sections were measured directly from the IMS-MS ex-
periment and modeling undertaken to probe potential
structures of the species measured. The modeling in this
case assumed each monomer to have a spherical shape
and from this the average cross-sectional area was
calculated using the projection approximation method
[46]. Following on from this, an overlap of some 10% of
monomer spheres was found to reproduce the experi-
mental cross-sectional area of the dimer, and this ad-
justment was used to model the higher-order oligomers
in this study. In the case of the A1-42 hexamer, a
modeled ring-like arrangement of monomers had the
closest calculated collision cross-section to that mea-
sured, compared with both straight chain and spherical
models. The A1-42 tetramer had a collision cross-
section which was consistent with a model of an angled
segment of the ring-like hexamer, with quite an open
structure affording sufficient space for subsequent
dimer addition to complete the ring and form the
hexamer. In contrast, the A1-40 tetramer was found to
have a smaller collision cross-section indicating a more
closed structure, which would not be disposed to the
addition of either a monomer or a dimer and hence
explaining why there was no evidence of the hexamer
or any higher order species for A1-40. From these [44]
and earlier [60] ESI-IMS-MS oligomer data, a global
scheme of amyloid- oligomerization was proposed in
which the A1-42 tetramer added a dimer to produce
the ring-shaped hexamer, which subsequently dimer-
ized to produce a two-ring, stacked dodecamer (Figure
3). Following this, it was suggested that the dodecamer
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formed -sheet fibrils. In the case of A1-40, the more
compact tetramer was proposed to undergo very slow
fibril formation, although this was not observed during
the time-scale of these experiments. This study indicates
the amount of detail that can be obtained simulta-
neously on a number of oligomeric species within a
heterogeneous ensemble.
Transmissible spongiform encephalopathies (TSEs),
often referred to as prion diseases, represent a group of
fatal neurodegenerative disorders associated with the
accumulation of amyloid fibrils that arise in mamma-
lian species and include bovine spongiform encepha-
lopathy in cattle, scrapie in sheep, and Creutzfeldt-
Jakob disease in humans. These fibrillar aggregates
result from the conversion of the normal cellular prion
protein (PrP) to an abnormal conformer, PrPSc, and
although PrP and PrPSc appear to share the same
covalent structure, they differ in biophysical properties
[63]. In an in vitro study of mouse and Syrian hamster
recombinant PrP proteins, both formed aggregates but
each with a distinct morphology: the mouse fibrils were
formed by twisted protofibrils whereas the hamster
fibrils had a diameter some 50% less. This study
Figure 3. Taken from [44] (Figure 3). (a) The arrival time distri-
butions (drift time (s) versus relative intensity) of A1-42 oli-
gomers (represented by the z/n  5/2 charge state) observed by
conventional IMS-MS with structural designations in place; (b) a
plausible mechanism for forming the oligomer distribution shown
in (a). Reprinted by permission from Macmillan Publishers Ltd:
Nat. Chem. 2009, 1, 326–331.demonstrated also that these 16 kDa proteins canadopt the -helical native isoform, two non-native
-sheet-rich isoforms, a -oligomer, and an amyloid
fibril. The preferences for forming either a -oligomer
or amyloid can be dictated by experimental conditions,
with acidic conditions favoring the former and neutral
conditions the latter. ESI-MS analysis of the -oligomer
indicated this species to be predominantly octameric
(129 kDa) but its biological significance has not yet
been determined [63]. A more recent study compared
the monomeric and oligomeric structures of normal
PrP106-126 (the protein domain thought to be involved
in amyloid formation) and two non-aggregating forms of
the peptide, an oxidized form in which both methionine
residues are oxidized to methionine sulphoxide and a
control peptide consisting of the same amino acids as
PrP106-126 in a scrambled sequence. Oligomers were
detected for the wild-type peptide only and molecular
dynamics simulations were carried out to explore the
relationship between sequence and structure of the
three peptides [64].
What Can We Learn About Amyloid Fibrils?
Despite details concerning the oligomeric states de-
tected en route to fibril formation beginning to emerge,
the question of how the polypeptide chains are wound
into the generic cross- structure of amyloid fibrils still
remains elusive. Although the MS analysis of intact
fibrils has not yet been reported, proteolysis followed
by MS(/MS) characterization of the cleaved peptide
fragments has been used to generate details of the
structural organization of the fibrillar structure. In
general, proteolysis of the intact fibril (either directly or
after HDX), followed by defibrillization and mass spec-
trometric analysis of the protein and resulting peptides,
has provided significant insights into the structural
characteristics of amyloid fibrils [65].
HDX offers insights into the extent of stable protein
structure and is therefore important for studying amy-
loid due to the characteristic, highly stable, -sheet fibril
architecture. The experimental procedure generally in-
volves the independent exposure of both the protein
monomer and the amyloid fibrils to deuterated solvent
for a specific time, after which the extent of deuteration
in each is measured by MS and compared. In the case of
the protein monomer, the deuteration level can be
measured on either the intact protein [66] or, to scruti-
nize specific amino acid residues, on peptides arising
from protein proteolysis [65, 67]. The deuterated fibrils
first need to be dissolved in dimethylsulphoxide to
regenerate monomer before being subjected to proteol-
ysis and analysis [65]. This approach has been applied
to a number of amyloid systems. In one such case, two
amyloidogenic variants of lysozyme were compared
with wild-type protein and were found to have un-
folded regions in the -domain and adjacent C-helix
[67]. Structural differences between A1-40 protofibrils
and fibrils have also been reported [68]: although the C-
and N-terminal fragments in both the fibrils and proto-
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internal peptide fragment consisting of residues 20–34
was found to be highly protected in fibrils, but not so in
protofibrils, suggesting that although the -sheet ele-
ments in the final fibrils may be present to some extent
in the protofibrils, the transition from protofibril to
fibril does involve significant ordering of this central
region.
The recombinant, 289-residue HET-s prion protein
analogue aggregates in vitro to produce infectious
amyloid fibrils. HDX of these fibrils followed by pepsin
proteolysis and matrix-assisted laser desorption ioniza-
tion (MALDI)-MS analysis indicated that the prion-
forming domain (corresponding to C-terminal residues
218–289) is highly protected in amyloid [69–71]. The
HDX time-course also indicated that deuterium in-
corporation in the C-terminal region of the protein
was drastically reduced in amyloid compared with
the monomer [69].
The HDX properties of insulin under amyloid fibril-
forming conditions have been explored with the results
indicating that the protected regions of the protein lie in
the A13-A19, A2-A8, and B chain helices, consistent
with insulin being in a predominantly helical confor-
mation under these conditions [72].
SH3 domains are small modules of 50 amino acid
residues found in many proteins involved in intracellular
signal transduction and have a characteristic -barrel fold
consisting of five or six -strands arranged as two anti-
parallel -sheets. The amyloid-forming properties of the
SH3 domain of bovine phosphatidylinositol-3-kinase
(PI3-SH3), an 86-residue protein, have been interro-
gated in vitro [12, 73]. Under acidic pH conditions,
P13-SH3 adopts a compact denatured state which
slowly forms a gel that consists of typical amyloid
fibrils [74]. During an HDX-ESI-MS study to probe the
nature of this amyloid structure, the fibrils were ex-
posed to deuterated buffer for varying lengths of time
and then solubilized into monomers using dimethylsul-
phoxide before analysis [73]. ESI-MS, with its ability to
detect coexisting populations of molecules with differ-
ent degrees of exchange, showed two well-resolved
peaks on HDX exposure, indicating that two distinct
isotopically labeled populations are present within the
amyloid fibrils: one representing an exchange of 50%
of the labile hydrogen atoms, the other almost complete
exchange. The explanation proposed suggested that an
ensemble of molecules within the fibrils is in dynamic
equilibrium with a pool of soluble protein monomers
(Figure 4), i.e., protein monomers dissociate from the
fibrils, undergo HDX when in solution, and are then
re-incorporated into the fibrils. Thus, two peaks are
observed: one that represents the population of mole-
cules not yet dissociated from fibrils, while the other
represents the population that has dissociated, ex-
changed, and been re-incorporated into fibrils. Support-
ing this molecular recycling model, it was found that
there is always a certain amount of soluble protein
monomer in the fibril-containing mixture. This impor-tant insight into the dynamic nature of the amyloid
fibrils has implications for the design of therapeutics.
2m amyloid fibrils have been the subject of several
investigative structural studies using limited proteoly-
sis followed byMS(/MS) analysis [75–78]. Comparisons
of the surface topology of fibrils arising from the intact
protein with that of fibrils formed from a truncated
species lacking the first six amino acid residues (N6-
2m; which is also found in ex vivo fibrils) have been
made [75; 77]. Both sets of fibrils were found to have a
fully protected central region, comprising residues 20–
87, and exposed C- and N-terminals. Limited proteoly-
sis of 2m amyloid fibrils followed by ESI-MS(/MS)
characterization of the resulting peptides illustrated
clear differences in the architecture of fibrils formed
Figure 4. Taken from [73] (Figure 4). Schematic representation of
the recycling process involving a single amyloid fibril. (a) A
protonated protein molecule (open circle) dissociates from the
fibril. Once in solution, HDX takes place rapidly and the molecule
is subsequently reincorporated in a fully deuterated state (filled
circle); (b) schematic representation of the recycling mechanism
for a distribution of amyloid fibrils at different times of exchange;
at a given time point the dissociation of a molecule from a fibril
(upper) is counteracted by the re-association of that molecule in
another fibril (lower). Reprinted by permission from Macmillan
Publishers Ltd.: Nature 2005, 436, 554–558.from partially unfolded (pH 3.6) and acid-unfolded (pH
1094 ASHCROFT J Am Soc Mass Spectrom 2010, 21, 1087–10962.5) protein monomer [76]. Despite having very differ-
ent morphologic properties, both types of fibril show
consistency with the common cross- configuration of
amyloid. This study found that the long, straight, pH
2.5 fibrils (similar to ex vivo fibrils) were highly resis-
tant to proteolysis and that 90% of the polypeptide
chain was involved in the fibril core. Compared with
this, the shorter, worm-like pH 3.6 fibrils were more
susceptible to proteolysis, and their protected core was
reduced to 30% of the protein. Particular differences
arose in strands B and F, close to the Cys25–Cys80
disulphide bond, which were protected in the long,
straight fibrillar structures but less so in the worm-like
fibrils, and also in the C-terminal region, which was
involved in the protected core in the pH 2.5 fibrils but
not in the pH 3.6 fibrils. The N-terminal 10 residues
were highly susceptible to proteolysis in both types of
fibrils.
Can We Prevent Amyloid Formation?
In addition to satisfying scientific curiosity, one of the
key driving forces behind amyloid research must be the
long-term goal of therapeutic design to prevent these
fatal, and currently, unstoppable, diseases. One ap-
proach may be to inhibit the formation of fibrils, but the
reported oligomer toxicity [59, 79, 80] indicates that
therapeutic strategies aimed at the destabilization of
fibrils may prove counter-productive as this could lead
to an increase in the level of oligomers.
A review some years ago highlighted a range of
different compound classes including dyes (e.g., Congo
red), rifamycin antibiotics, anthracycline derivatives,
Figure 5. Taken from [81] (Figure 2). The ultr
inhibition of A aggregation. After incubation
protein is removed by ultrafiltration and the res
with the amount remaining in an untreated
aggregation produce solutions with the highest
permission from Analytical Chemistry: Anal. C
Chemical Society.acridinones, benzofurans, and peptides, which had
been found to inhibit the formation of A fibrils. This
behavior had been detected using biophysical tech-
niques, such as light scattering, dye binding, EM, and
AFM [79]—but not mass spectrometry! However, a
high-throughput, sensitive, MS-based screening assay
has been reported for potential A1-40 protein aggre-
gation inhibitors: the procedure involves incubation of
A1-40 with test compounds, followed by separation of
the residual monomer from any aggregates, and then
quantification of the monomer using ESI-MS (Figure 5)
[81]. The greater the concentration of residual monomer
indicates a greater degree of inhibition of aggregation,
and the order of inhibition for the compounds screened
in this study was: daunomycin  3-indolepropionic
acid  melatonin  methysticin.
-Synuclein, a 140-amino acid residue presynaptic
brain protein, is a major fibrillar component of Lewy
bodies and hence associated with the loss of brain cells
resulting in Parkinson’s disease. The inhibitory effect in
vivo of the antibiotic rifampicin on -synuclein aggre-
gation, and also its ability to disassociate preformed
fibrils, has been reported [80]. The data suggest that
such inhibition is due to the stabilization of the protein
monomer and soluble, low order oligomers. ESI-MS
was used to examine -synuclein after incubation in the
presence and absence of rifampicin; as no change to the
protein was detected, covalent modification was ruled
out [80].
A recent study whereby the effect of a single-domain
fragment of a camelid heavy-chain antibody, specific
for the active site of human lysozyme, on two amyloi-
dogenic variants of this protein, was investigated [82].
ation ESI-MS screening assay to test for ligand
1-40 with a test compound, any aggregated
l protein monomer is quantified by comparison
40 solution. Compounds that prevent A1-40
entration of A1-40 monomer. Reprinted with
2005, 77, 7012–7015. Copyright 2005, Americanafiltr
of A
idua
A1-
conc
hem.
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inhibited unfolding of the protein monomer. A more
stable, disulphide-bridged version of the antibody was
found to inhibit lysozyme fibril formation, suggesting
that molecular targeting of enzyme-active sites, and
consequently of protein binding sites, is an effective
strategy for inhibiting self-assembly.
Future Directions
How far have we come with the amyloid problem in the
gas phase? Co-populated protein conformers have been
detected and separated, protein monomer consumption
during fibril assembly has been assessed, the appear-
ance and decline of oligomers—which have been iden-
tified by their mass and physical shape—have been
measured during self-aggregation, and approaches to
amyloid inhibition are now being reported. However,
there is no respite as there remains much to achieve,
especially in terms of defining the pathway from oli-
gomers to the final fibrillar structures, and in identify-
ing therapeutic remedies.
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